{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:36:20Z","timestamp":1792427780577,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013412","name":"Sanofi Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013412","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017255","name":"Allergy Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017255","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019718","name":"Boehringer Ingelheim Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019718","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004357","name":"Procter and Gamble","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004357","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019719","name":"Chiesi Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019719","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019720","name":"GlaxoSmithKline Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019720","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019721","name":"Roche Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019721","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.jaip.2022.04.039","type":"journal-article","created":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T23:01:36Z","timestamp":1652310096000},"page":"2438-2447.e9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Management of United Airway Disease Focused on Patients With Asthma and Chronic Rhinosinusitis With Nasal Polyps: A Systematic Review"],"prefix":"10.1016","volume":"10","author":[{"given":"Joaquim","family":"Mullol","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Maldonado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 A.","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Miguel-Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"D\u00e1vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Dom\u00ednguez-Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Blanco-Aparicio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2022.04.039_bib1","first-page":"27","article-title":"Regulation of interaction between the upper and lower airways in united airway disease","volume":"7","author":"Kanda","year":"2019","journal-title":"Med Sci (Basel)"},{"key":"10.1016\/j.jaip.2022.04.039_bib2","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1111\/all.13496","article-title":"Precision medicine in united airways disease: a \u201ctreatable traits\u201d approach","volume":"73","author":"Yii","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2022.04.039_bib3","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.jaip.2020.09.063","article-title":"Chronic rhinosinusitis with nasal polyps and asthma","volume":"9","author":"Laidlaw","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.04.039_bib4","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1111\/all.13875","article-title":"EUFOREA consensus on biologics for CRSwNP with or without asthma","volume":"74","author":"Fokkens","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2022.04.039_bib5","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2500\/ajra.2011.25.3613","article-title":"Association between severity of asthma and degree of chronic rhinosinusitis","volume":"25","author":"Lin","year":"2011","journal-title":"Am J Rhinol Allergy"},{"key":"10.1016\/j.jaip.2022.04.039_bib6","first-page":"24","article-title":"Type 2 Inflammation and the evolving profile of uncontrolled persistent asthma","volume":"3","author":"Diamant","year":"2018","journal-title":"Eur Med J"},{"key":"10.1016\/j.jaip.2022.04.039_bib7","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jaci.2020.04.040","article-title":"Type 2 inflammation in chronic rhinosinusitis without nasal polyps: another relevant endotype","volume":"146","author":"Delemarre","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.04.039_bib8","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11882-020-00905-9","article-title":"NSAID-ERD syndrome: the new hope from prevention, early diagnosis, and new therapeutic targets","volume":"20","author":"Laidlaw","year":"2020","journal-title":"Curr Allergy Asthma Rep"},{"key":"10.1016\/j.jaip.2022.04.039_bib9","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/all.13599","article-title":"Diagnosis and management of NSAID-exacerbated respiratory disease (N-ERD)\u2014a EAACI position paper","volume":"74","author":"Kowalski","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2022.04.039_bib10","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/j.jaci.2021.08.015","article-title":"Eicosanoid dysregulation and type 2 inflammation in AERD","volume":"148","author":"Mullol","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.04.039_bib11","doi-asserted-by":"crossref","first-page":"101332","DOI":"10.1016\/j.smim.2019.101332","article-title":"Immunological biomarkers in severe asthma","volume":"46","author":"Narendra","year":"2019","journal-title":"Semin Immunol"},{"key":"10.1016\/j.jaip.2022.04.039_bib12","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/j.jaip.2020.03.038","article-title":"Prospective, single-arm, longitudinal study of biomarkers in real-world patients with severe asthma","volume":"8","author":"Buhl","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.04.039_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4193\/Rhin20.401","article-title":"European position paper on rhinosinusitis and nasal polyps 2020","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"key":"10.1016\/j.jaip.2022.04.039_bib14","series-title":"Asthma Management and Prevention for Adults and Children Older than 5 Years","year":"2021"},{"key":"10.1016\/j.jaip.2022.04.039_bib15","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.arbres.2021.05.010","article-title":"Spanish asthma management guidelines (GEMA) VERSION 5.1. Highlights and controversies","volume":"58","author":"Plaza","year":"2022","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.jaip.2022.04.039_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.jaip.2022.04.039_bib17","first-page":"ED000142","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaip.2022.04.039_bib18","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.anai.2020.03.004","article-title":"A\u00a0real-world assessment of asthma with chronic rhinosinusitis","volume":"125","author":"Ricciardolo","year":"2020","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2022.04.039_bib19","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/jama.2015.19330","article-title":"Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial","volume":"315","author":"Bachert","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jaip.2022.04.039_bib20","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jaip.2022.04.039_bib21","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.anai.2021.01.012","article-title":"Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma","volume":"126","author":"Laidlaw","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaip.2022.04.039_bib22","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jaip.2019.07.016","article-title":"Dupilumab efficacy in uncontrolled, moderate-to-severe asthma with self-reported chronic rhinosinusitis","volume":"8","author":"Maspero","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.04.039_bib23","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/cea.13954","article-title":"Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases","volume":"51","author":"Hamilton","year":"2021","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2022.04.039_bib24","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.04.039_bib25","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.jaci.2017.05.044","article-title":"Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial","volume":"140","author":"Bachert","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.04.039_bib26","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2500\/aap.2020.41.200069","article-title":"Chronic rhinosinusitis with nasal polyps management in the age of biologics","volume":"41","author":"Blaiss","year":"2020","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.jaip.2022.04.039_bib27","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Han","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2022.04.039_bib28","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2147\/JAA.S288260","article-title":"Efficacy of tezepelumab in patients with severe, uncontrolled asthma with and without nasal polyposis: a post hoc analysis of the Phase 2b PATHWAY Study","volume":"14","author":"Emson","year":"2021","journal-title":"J\u00a0Asthma Allergy"},{"key":"10.1016\/j.jaip.2022.04.039_bib29","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaci.2020.11.013","article-title":"EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: definitions and management","volume":"147","author":"Bachert","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2022.04.039_bib30","doi-asserted-by":"crossref","first-page":"240","DOI":"10.5114\/ada.2020.94842","article-title":"Serum periostin levels in asthma patients in relation to omalizumab therapy and presence of chronic rhinosinusitis with nasal polyps","volume":"37","author":"Novosad","year":"2020","journal-title":"Postepy Dermatol Alergol"},{"key":"10.1016\/j.jaip.2022.04.039_bib31","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/all.14611","article-title":"Dupilumab is effective in type 2-high asthma patients receiving high-dose inhaled corticosteroids at baseline","volume":"76","author":"Bourdin","year":"2021","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2022.04.039_bib32","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2022.04.039_bib33","doi-asserted-by":"crossref","first-page":"190085","DOI":"10.1183\/16000617.0085-2019","article-title":"How can we minimise the use of regular oral corticosteroids in asthma?","volume":"29","author":"Bourdin","year":"2020","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.jaip.2022.04.039_bib34","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.pupt.2018.11.002","article-title":"Omalizumab lowers asthma exacerbations, oral corticosteroid intake and blood eosinophils: results of a 5-YEAR single-centre observational study","volume":"54","author":"Pelaia","year":"2019","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.jaip.2022.04.039_bib35","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1016\/j.jaip.2021.01.011","article-title":"Real-world effectiveness of omalizumab in severe allergic asthma: a meta-analysis of observational studies","volume":"9","author":"Bousquet","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.04.039_bib36","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid\u2013sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaip.2022.04.039_bib37","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S2213-2600(20)30397-0","article-title":"Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial","volume":"9","author":"Heaney","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jaip.2022.04.039_bib38","first-page":"301","article-title":"Dupilumab reduces systemic corticosteroid use and sinonasal surgery rate in CRSwNP","volume":"59","author":"Desrosiers","year":"2021","journal-title":"Rhinology"},{"key":"10.1016\/j.jaip.2022.04.039_bib39","article-title":"Impact of chronic rhinosinusitis on severe asthma patients","volume":"12","author":"Lee","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.jaip.2022.04.039_bib40","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1080\/02770903.2020.1729380","article-title":"Impact of sinus surgery on type 2 airway and systemic inflammation in asthma","volume":"58","author":"Hamada","year":"2021","journal-title":"J\u00a0Asthma"},{"key":"10.1016\/j.jaip.2022.04.039_bib41","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1159\/000509253","article-title":"Increased serum periostin levels and eosinophils in nasal polyps are associated with the preventive effect of endoscopic sinus surgery for asthma exacerbations in chronic rhinosinusitis patients","volume":"181","author":"Kanemitsu","year":"2020","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2022.04.039_bib42","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1002\/alr.22780","article-title":"Efficacy of dupilumab in patients with a history of prior sinus surgery for chronic rhinosinusitis with nasal polyps","volume":"11","author":"Hopkins","year":"2021","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jaip.2022.04.039_bib43","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1016\/j.jaip.2019.03.044","article-title":"Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERD","volume":"7","author":"Laidlaw","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.04.039_bib44","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.jaip.2021.01.031","article-title":"Indirect treatment comparison of biologics in chronic rhinosinusitis with nasal polyps","volume":"9","author":"Peters","year":"2021","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.04.039_bib45","doi-asserted-by":"crossref","DOI":"10.1177\/2058738420950851","article-title":"Real-life effects of benralizumab on allergic chronic rhinosinusitis and nasal polyposis associated with severe asthma","volume":"34","author":"Lombardo","year":"2020","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.jaip.2022.04.039_bib46","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jaip.2018.01.038","article-title":"A\u00a0retrospective analysis of mepolizumab in subjects with aspirin-exacerbated respiratory disease","volume":"6","author":"Tuttle","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.04.039_bib47","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1164\/rccm.201906-1215OC","article-title":"Omalizumab for aspirin hypersensitivity and leukotriene overproduction in aspirin-exacerbated respiratory disease. a randomized controlled trial","volume":"201","author":"Hayashi","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2022.04.039_bib48","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jaip.2018.08.021","article-title":"Effects of reslizumab on asthma outcomes in a subgroup of eosinophilic asthma patients with self-reported chronic rhinosinusitis with nasal polyps","volume":"7","author":"Weinstein","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2022.04.039_bib49","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.3389\/fphar.2020.01147","article-title":"NSAID-exacerbated respiratory disease (NERD): from pathogenesis to improved care","volume":"11","author":"Woo","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jaip.2022.04.039_bib50","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1111\/all.15067","article-title":"Efficacy and safety of dupilumab in patients with uncontrolled severe CRSwNP and a clinical diagnosis of NSAID-ERD: results from two randomized placebo-controlled phase 3 trials","volume":"77","author":"Mullol","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2022.04.039_bib51","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1002\/alr.22851","article-title":"Multidisciplinary consensus on a stepwise treatment algorithm for management of chronic rhinosinusitis with nasal polyps","volume":"11","author":"Han","year":"2021","journal-title":"Int Forum Allergy Rhinol"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219822004846?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219822004846?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:35:37Z","timestamp":1761975337000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219822004846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":51,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S2213219822004846"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2022.04.039","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of United Airway Disease Focused on Patients With Asthma and Chronic Rhinosinusitis With Nasal Polyps: A Systematic Review","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2022.04.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}